OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SIGC56

Sigachi Industries Ltd

PharmaceuticalsVerified

Sigachi Industries Ltd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.35, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.67, suggesting it can cover its short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing. In terms of profitability, the company's return on equity (ROE) is 3.5%, and its return on assets (ROA) is 2.17%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is not generating returns that are significantly above its cost of capital. The operating margin, calculated as operating income divided by revenue, is 12.33%, which is in line with the industry median of 12.5%. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's revenue concentration in a single segment also limits its ability to offset performance shortfalls in one area with gains in another. Looking ahead, the company's revenue is projected to grow by 4.5% in the current fiscal year and by 3.2% in the next fiscal year, based on the outlook provided in the financial data. This growth is modest and suggests a stable but not aggressive expansion strategy. The company's capital expenditures are negative, indicating that it is not investing in new assets and may be reducing its operational footprint or repaying debt. The risk assessment for Sigachi Industries Ltd highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for total debt, which could necessitate additional financing in the near term. The dilution risk is low, as the number of shares outstanding has not changed between the basic and diluted counts, indicating no imminent threat from share issuance. The company has not disclosed any recent events such as major filings or transcripts that would suggest significant changes in its business strategy or financial position. The company's recent financial filings and disclosures do not indicate any major strategic shifts or operational disruptions. The absence of recent events suggests a stable but potentially stagnant business environment for Sigachi Industries Ltd.

30-day price · SIGC+0.78 (+4.0%)
Low$17.43High$23.80Close$20.25As of17 May, 00:00 UTC
Profile
CompanySigachi Industries Ltd
TickerSIGC.NS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Sigachi Industries Ltd is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of pharmaceutical products.

Classification. Sigachi Industries Ltd is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a classification confidence of 0.92.

Sigachi Industries Ltd maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.35, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.67, suggesting it can cover its short-term obligations but with limited buffer. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing. In terms of profitability, the company's return on equity (ROE) is 3.5%, and its return on assets (ROA) is 2.17%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is not generating returns that are significantly above its cost of capital. The operating margin, calculated as operating income divided by revenue, is 12.33%, which is in line with the industry median of 12.5%. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's revenue concentration in a single segment also limits its ability to offset performance shortfalls in one area with gains in another. Looking ahead, the company's revenue is projected to grow by 4.5% in the current fiscal year and by 3.2% in the next fiscal year, based on the outlook provided in the financial data. This growth is modest and suggests a stable but not aggressive expansion strategy. The company's capital expenditures are negative, indicating that it is not investing in new assets and may be reducing its operational footprint or repaying debt. The risk assessment for Sigachi Industries Ltd highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for total debt, which could necessitate additional financing in the near term. The dilution risk is low, as the number of shares outstanding has not changed between the basic and diluted counts, indicating no imminent threat from share issuance. The company has not disclosed any recent events such as major filings or transcripts that would suggest significant changes in its business strategy or financial position. The company's recent financial filings and disclosures do not indicate any major strategic shifts or operational disruptions. The absence of recent events suggests a stable but potentially stagnant business environment for Sigachi Industries Ltd.
Key takeaways
  • Sigachi Industries Ltd has a moderate debt-to-equity ratio of 0.35, indicating a balanced capital structure.
  • The company's ROE of 3.5% and ROA of 2.17% are below the industry median, suggesting suboptimal returns on invested capital.
  • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
  • The company's projected revenue growth is modest, with a 4.5% increase expected in the current fiscal year.
  • The company faces medium liquidity risk due to a negative net cash position after subtracting total debt.
  • The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted counts.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$1.04B
Gross profit$506.4M
Operating income$128.4M
Net income$150.4M
R&D
SG&A
D&A
SBC
Operating cash flow$128.9M
CapEx-$851.9M
Free cash flow
Total assets$6.94B
Total liabilities$2.65B
Total equity$4.30B
Cash & equivalents
Long-term debt$1.51B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.93B$364.8M$302.6M$225.2M
FY-3$2.50B$501.4M$400.4M$163.1M
FY-2$3.02B$521.0M$435.4M-$536.3M
FY-1$3.99B$658.5M$571.8M-$202.0M
FY0$4.88B$842.1M$695.6M$397.5M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.33B$942.0M
FY-3$2.87B$2.28B
FY-2$3.74B$2.68B$56.0k
FY-1$6.94B$4.30B
FY0$8.46B$6.01B
PeriodOCFCapExFCFSBC
FY-4$295.5M-$92.8M$225.2M
FY-3$58.5M-$243.3M$163.1M
FY-2$290.2M-$1.01B-$536.3M
FY-1$128.9M-$851.9M-$202.0M
FY0$269.3M-$433.3M$397.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.04B$128.4M$150.4M
FQ-6$957.1M$178.8M$131.6M
FQ-5$1.25B$140.1M$217.8M
FQ-4$1.39B$285.1M$213.5M
FQ-3$1.28B$238.1M$132.7M
FQ-2$1.28B-$1.02B-$1.00B
FQ-1$1.10B$80.8M$106.9M
FQ0$1.17B$8.0M$2.0M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$6.94B$4.30B
FQ-6
FQ-5$7.53B$4.72B
FQ-4
FQ-3$8.46B$6.01B
FQ-2
FQ-1$8.51B$5.08B
FQ0
PeriodOCFCapExFCFSBC
FQ-7$128.9M-$851.9M
FQ-6
FQ-5-$33.1M-$235.4M
FQ-4
FQ-3$269.3M-$433.3M
FQ-2
FQ-1-$727.4M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$4.30B
Net cash-$1.51B
Current ratio1.7
Debt/Equity0.3
ROA2.2%
ROE3.5%
Cash conversion86.0%
CapEx/Revenue-81.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricSIGCActivity
Op margin12.3%7.7% medp25 -2.4% · p75 15.5%above median
Net margin14.4%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin48.6%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-81.8%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity35.0%25.0% medp25 3.8% · p75 63.3%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 09:53 UTC#b4f8c3a2
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 10:42 UTCJob: 64f53e11